Zobrazeno 1 - 4
of 4
pro vyhledávání: '"O M, Aleksyk"'
Autor:
L A, Syvak, H O, Hubareva, K S, Filonenko, N M, Majdanevych, O M, Aleksyk, S A, Lyalkin, M J, Klimanov, A V, Askolskyi, N V, Kasap
Publikováno v:
Likars'ka sprava. (3-4)
The use of modern chemotherapy (CT) allowed to achieve significant progress in the treatment of many malignant tumors that were previously considered fatal. Improving the efficiency of the treatment was achieved by the intensification of chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::891288ae09ad6727ee24585413f255ed
https://pubmed.ncbi.nlm.nih.gov/26827433
https://pubmed.ncbi.nlm.nih.gov/26827433
Autor:
I A, Kryachok, O M, Aleksyk
Publikováno v:
Likars'ka sprava. (12)
Diagnosis and treatment patients with lymphoma is still obe of the main problems in theoretical and clinical oncology. Observing increasing tendency of lymphoma incidence in Ukraine it should be noted that the disease is prevalent in young and workin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bedcc90ef2d42d78e5486fbeb7707559
https://pubmed.ncbi.nlm.nih.gov/26638466
https://pubmed.ncbi.nlm.nih.gov/26638466
Autor:
O I, Novosad, I A, Kriachok, T V, Kadnikova, K S, Filonenko, I B, Tytorenko, A V, Martynchyk, O M, Aleksyk, Iu O, Gusachenko, I A, Filonenko
Publikováno v:
Likars'ka sprava. (3-4)
Achievements of world practice about development and prophilaxis of tromboembolic events (VTE) in cancer patients. Particular attention is paid to prevention of VTE in patients with multiply myeloma who receive chemotherapy with Thalidomide.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1b40352621b68886488611a730d83967
https://pubmed.ncbi.nlm.nih.gov/22416363
https://pubmed.ncbi.nlm.nih.gov/22416363
Autor:
H O, Hubareva, I A, Kriachok, I B, Tytorenko, O M, Aleksyk, O I, Novosad, T V, Kadnikova, A V, Martynchyk, Ia V, Pastushenko, K S, Filonenko, Ie V, Kushchevyĭ
Publikováno v:
Likars'ka sprava. (1-2)
The treatment of patients with refractory forms of Hodgkin's lymphomas in combination with chemo-radiotherapy is priority. Nevertheless, chemotherapy has to include multicomponent schemes and radiation therapy should be an addition and consolidative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c87d75a3b07ecdb8ae851ac011ff4c4c
https://pubmed.ncbi.nlm.nih.gov/20608037
https://pubmed.ncbi.nlm.nih.gov/20608037